Killer Cells, Lymphokine-Activated - Chemistry
Research News and Information

Monday, November 23, 2009

Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial.

10 Nov 2008 Eighty women undergoing multimodality treatment for large (>4cm) or locally advanced (T3, T4, Tx, N2), breast cancers participated in a randomised controlled trial (RCT) to evaluate the immuno-modulatory effects of relaxation training and guided ... Read more...

A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.

26 Jun 2007 Natural killer (NK) cell-or T cell-mediated cytotoxicity traditionally is measured in 4-16 h (51)Cr-release assays (CRA). A new four-color flow cytometry-based cytotoxicity assay (FCC) was developed to simultaneously measure NK cell cytotoxicity and ... Read more...

Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.

31 Jan 2007 Despite successes in animals, cytokine gene expression selectively in human tumors is difficult to achieve owing to lack of efficient delivery methods. Since interleukin (IL)-2-activated natural killer (A-NK) and phytohemagglutinin and IL-2 ... Read more...

Latest indexed articles for 'Killer Cells, Lymphokine-Activated - Chemistry'

These are the very latest articles for this heading:

• Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial. 10 Nov 2008
• A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. 26 Jun 2007
• Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells. 31 Jan 2007
• [E. coli-based production of recombinant HMG-17 and its antibacterial domain] 30 Jul 2005
• [Isolation and purification of antibacterial polypeptides from human LAK cells] 30 Dec 2001
• Characterization of four new monoclonal antibodies that recognize mouse natural killer activation receptors. 30 Mar 2001
• A new monoclonal antibody reactive with several Ly49 NK cell receptors mediates redirected lysis of target cells. 30 Jul 1999
• NCCRP-1: a novel receptor protein sequenced from teleost nonspecific cytotoxic cells. 30 Jul 1997
• Lipid structure of cytotoxic granules in living human killer T lymphocytes studied by Raman microspectroscopy. 15 Apr 1997
• Interactions of lymphokine-activated killer cells and A549 lung carcinoma nodules maintained in three-dimensional culture. 30 Dec 1996
• Morphologic and functional characterization of perforin-deficient lymphokine-activated killer cells. 13 Jul 1995
• Heat-shock proteins protect cells from monocyte cytotoxicity: possible mechanism of self-protection. 30 Dec 1992
• Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset. 30 Dec 1992
• Identification and partial characterization of a novel plasma membrane-associated lytic factor isolated from highly purified adherent lymphokine-activated killer cells. 13 Apr 1992
• Leukophysin: a 28-kDa granule membrane protein of leukocytes. 30 Oct 1991
• Rapid loss of perforin and serine protease RNA in cytotoxic lymphocytes exposed to sensitive targets. 29 Sep 1991
• Mouse NKR-P1. A family of genes selectively coexpressed in adherent lymphokine-activated killer cells. 30 Aug 1991
• Subcellular localization of perforin and serine esterase in lymphokine-activated killer cells and cytotoxic T cells by immunogold labeling. 13 Jun 1991
• Expression of membrane-associated lymphotoxin/tumor necrosis factor-beta on human lymphokine-activated killer cells. 30 Dec 1990

See a longer list of these articles.

Technical information about 'Killer Cells, Lymphokine-Activated'

Definition: Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.

Descriptor UI: D015979

Alternative terms: Killer Cells, Lymphokine-Activated; Cell, Lymphokine-Activated Killer; Cells, Lymphokine-Activated Killer; Killer Cell, Lymphokine-Activated; Killer Cells, Lymphokine Activated; Lymphokine-Activated Killer Cell; Lymphokine-Activated Killer Cells; Lymphokine Activated Killer Cells; LAK Cells; Cell, LAK; Cells, LAK; LAK Cell;

Related Mesh Headings: Interleukin-2; Immunotherapy, Adoptive;

Allowable Qualifiers: classification; cytology; drug effects; enzymology; immunology; metabolism; microbiology; parasitology; pathology; physiology; radiation effects; radiography; radionuclide imaging; secretion; transplantation; ultrastructure; ultrasonography; chemistry; virology;

Tree Number: A11.118.637.555.283.500; A11.118.637.555.567.537.500; A15.145.229.637.555.283.500; A15.145.229.637.555.567.537.500; A15.382.490.555.283.500; A15.382.490.555.567.537.500;

History Note: 90

Technical Notes: if subpopulations are discussed, coordinate IM with LYMPHOCYTE SUBSETS (IM)